ArticleFrontiers in public health2023

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.

Yunlin Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.